A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Norman Wolmark, MD
NSABP Foundation Inc
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cleveland Clinic Weston
Weston, Florida, United States
- Cancer Care Specialists of Central Illinois
Decatur, Illinois, United States
- Crossroads Cancer Center
Effingham, Illinois, United States
- Cancer Care Specialists of Central Illinois-Swansea
Swansea, Illinois, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Stephenson Cancer Center at the University of Oklahoma Health Services Center
Oklahoma City, Oklahoma, United States
- Upmc- Hillman Cancer Center-Monroeville
Monroeville, Pennsylvania, United States
- Alleheny General Hospital
Pittsburgh, Pennsylvania, United States
- Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- Magee Womens Hospital of Upmc
Pittsburgh, Pennsylvania, United States
- Upmc Hillman Cancer Center North Hills at Passavant
Pittsburgh, Pennsylvania, United States
- Upmc- St. Margaret
Pittsburgh, Pennsylvania, United States
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
- Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
- West Virginia University
Morgantown, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2014
- Primary completion
- 31 Dec 2020
- Completion
- 31 Aug 2021
- Last update posted
- 26 Jan 2023
- Registered enrollment
- 49
- Registry id
- NCT02236000
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.